Posted by Michael Wonder on 14 Mar 2022
China NMPA approves tislelizumab for patients with microsatellite instability-high or mismatch repair-deficient solid tumours
11 March 2022 - Tislelizumab is now approved in seven indications in China.
BeiGene today announced that the China National Medical Products Administration has granted conditional approval to BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of adult patients with advanced unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours, including:
- Patients with advanced colorectal cancer who had been treated with fluoropyrimidine, oxaliplatin and irinotecan; and
- Other advanced solid tumours who develop disease progression after prior treatment and have no satisfactory alternative treatment options.
